Assessment of a DNA-PK Inhibitor as a Chemo-potentiating Agent in Osteosarcoma

被引：0
|
作者：
O'Reilly, E. [1 ]
Vormoor, B. [1 ]
Kyle, S. [1 ]
Newell, H. [1 ]
机构：
[1] No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72087-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
289
引用
收藏
页码：88 / 89
页数：2
相关论文
共 50 条
  • [21] Synthesis and Development of Prodrug BCCA621C: a Hypoxia Triggered DNA-PK Inhibitor
    Lindquist, K.
    Cran, J.
    Kordic, K.
    Winters, G.
    Chua, P.
    Tan, J.
    Kyle, A.
    Smith, M.
    Minchinton, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 86 - 86
  • [22] DNA-PK inhibitor wortmannin enhances DNA damage induced by bleomycin in V79 Chinese hamster cells
    Oliveira, NG
    Castro, M
    Rodrigues, AS
    Gil, OM
    Toscano-Rico, JM
    Rueff, J
    TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS, 2002, 22 (05): : 343 - 351
  • [23] AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
    Jacqueline H. L. Fok
    Antonio Ramos-Montoya
    Mercedes Vazquez-Chantada
    Paul W. G. Wijnhoven
    Valeria Follia
    Neil James
    Paul M. Farrington
    Ankur Karmokar
    Sophie E. Willis
    Jonathan Cairns
    Jenni Nikkilä
    David Beattie
    Gillian M. Lamont
    M. Raymond V. Finlay
    Joanne Wilson
    Aaron Smith
    Lenka Oplustil O’Connor
    Stephanie Ling
    Stephen E. Fawell
    Mark J. O’Connor
    Simon J. Hollingsworth
    Emma Dean
    Frederick W. Goldberg
    Barry R. Davies
    Elaine B. Cadogan
    Nature Communications, 10
  • [24] An improved synthetic strategy for the multigram-scale synthesis of DNA-PK inhibitor AZD7648
    Cai, Tian
    Yang, Xuebo
    Wang, Xuena
    Qin, Huanhuan
    Kang, Binghao
    Li, Bo
    Xing, Kun
    Huang, Min
    Zhao, Linxiang
    CHEMICAL PAPERS, 2024, 78 (05) : 2695 - 2728
  • [25] AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
    Fok, Jacqueline H. L.
    Ramos-Montoya, Antonio
    Vazquez-Chantada, Mercedes
    Wijnhoven, Paul W. G.
    Follia, Valeria
    James, Neil
    Farrington, Paul M.
    Karmokar, Ankur
    Willis, Sophie E.
    Cairns, Jonathan
    Nikkila, Jenni
    Beattie, David
    Lamont, Gillian M.
    Finlay, M. Raymond, V
    Wilson, Joanne
    Smith, Aaron
    O'Connor, Lenka Oplustil
    Ling, Stephanie
    Fawell, Stephen E.
    O'Connor, Mark J.
    Hollingsworth, Simon J.
    Dean, Emma
    Goldberg, Frederick W.
    Davies, Barry R.
    Cadogan, Elaine B.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [26] Antitumor activity of mTOR kinase and DNA-PK inhibitor CC-115 in a mouse model of glioblastoma
    Raymon, H.
    Peng, S.
    Katz, J.
    Zhao, C.
    Phan, C.
    Moghaddam, M. F.
    Fultz, K. E.
    Sankar, S.
    Mortensen, D. S.
    Narla, R. K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 170 - 170
  • [27] A multikinase inhibitor and DNA-PK inhibitor combination reduces tumor growth and alters the tumor microenvironment of B16 melanoma
    Tsai, Alexander
    Davila, Eduardo
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [28] Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy
    Boucher, D.
    Hillier, S.
    Newsome, D.
    Wang, Y.
    Takemoto, D.
    Gu, Y.
    Markland, W.
    Hoover, R.
    Arimoto, R.
    Maxwell, J.
    Fields, S. Z.
    Charifson, P.
    Penney, M. S.
    Tanner, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] DNA-PK inhibitor, M3814, as a new combination partner of Mylotarg in the treatment of acute myeloid leukemia
    Zimmermann, Astrid
    Carr, Michael
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2019, 79 (13)
  • [30] DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
    Carr, Michael, I
    Zimmermann, Astrid
    Chiu, Li-Ya
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    FRONTIERS IN ONCOLOGY, 2020, 10
12345